Status: Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
Participants needed: 120
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Taiho Oncology, Inc.Updated: Jun 26, 2026Locations: 65
Eligibility criteria
Histologically or cytologically confirmed, locally advanced, metastatic, or unre... [+6]
History or current evidence of calcium and phosphate homeostasis disorder [+14]